Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

HALO-202 is phase II study that randomized previously untreated patients with metastatic pancreatic ductal adenocarcinoma to PEGPH20 in addition to standard gemcitabine and abraxane versus standard gemcitabine and abraxane alone.

<<<

View more from the 2017 World Congress on GI Cancer